


# RSVoice Study

## Moderna

RSVoice aimed to evaluate the safety and immune response of an investigational vaccine aimed at preventing RSV infection in high risk adults.

Discover how uMed helped the study sponsor meet their challenging recruitment targets, using EHR screening, multi-modal engagement, and rigorous nurse follow-up to refer patients matching the study's narrow criteria.



### Key outcomes



**4,766**

total engagements sent via SMS and email



**650**

nurse follow-up calls boosted patient participation



**25%**

of referred patients were randomised



**#1**

Supported the top recruiting trial site in the UK with high quality referrals

## Overview

RSV is frequently associated with the risk it brings to young children, but the virus also poses a high risk for adults with pre-existing health conditions and older adults.

Hospitalization rates due to RSV in people with chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), asthma, and diabetes have been found to be higher than the rates in patients without these conditions.

The RSVoice study was evaluating the safety and immune response of an investigational vaccine (mRNA-1345) aimed at preventing RSV infection in high risk adults over the age of 18 years old. The study aimed to recruit participants from several disease groups including COPD, asthma, diabetes, coronary artery disease (CAD) and congestive heart failure (CHF).

## Study Objectives

Recruitment targets were quickly achieved for patients with COPD, asthma and diabetes due to the higher prevalence of these diseases amongst younger individuals. However randomisation of patients with a diagnosis of CAD and CHF was a challenge for the study sites, because these diseases are less common in younger cohorts. To address this, uMed was assigned the task of maximising randomisation of patients with a diagnosis of these diseases.

## Our Strategies for Success



uMed's vast healthcare research network provided access to a large patient population, **maximising the opportunity to reach the target cohort.**



Patient identification via EHR, **minimised screening failures down the line.**




**Multimodal patient outreach**, via SMS and email on behalf of the healthcare provider, and nurse follow-up, increased conversions.



Digital questionnaires provided an **additional screening step, increasing the likelihood of randomisation.**



**Nurse calls made to every CAD/CHF patient** boosted participation & ensured high quality referrals to increase randomisations.



“ I have been involved in several research studies and I have to say the uMed team was fantastic. They were very friendly and made participating in the RSVoice clinical trial easy. ”

Sebastian Grant  
RSVoice Study Participant

“ We have just been informed that we were the top recruiting site in the UK! So, thank you for all your hard work in helping us achieve this milestone! I would just like to take this opportunity to say on behalf of myself and the team here at LSTM, it has been a pleasure working with you all and I hope our paths cross again in the future. ”

Lauren McLellan  
Project Officer, Liverpool Life Sciences Accelerator (Liverpool School for Tropical Medicine)

uMed<sup>+</sup>

To understand how uMed can help you meet your recruitment targets, contact us at [hello@umed.io](mailto:hello@umed.io).